Exploring Novel Hallmark of Aging Targeting Strategies & Defining Quantitative Endpoints to Enhance Translatability & Clinical Success
Welcome to the 6th Age-Related Disease Therapeutics Summit
The Only Industry-Led Event Dedicated to Accelerating the Development of Treatments for Age-Related Diseases
Age-related disease biotechs are set to shine in 2024, but to successfully navigate the volatile market of 2024, rapid proof-of-concept studies and validated clinical endpoints are crucial for funding and pipeline progress.
The 6th Age-Related Disease Therapeutics Summit is reconvening in San Francisco this June as the only industry-led meeting for longevity biotechs to demonstrate clinically validated data to large pharma and investors to form commercial long-term partnerships, and together propel late stage commercialization.
Across 3-days of content in 2024, we are proud to unite:
- Eli Lilly and Takeda to illustrate what they are looking for and why they care about longevity therapeutics for future portfolio diversification
- BioAge, Dorian Therapeutics, Fauna Bio, Fountain Therapeutics, Loxo@Lilly, NeuroAge Therapeutics, Rubedo Life Sciences, SMS Biotech, Turn.Bio to showcase how they navigate complex regulatory environment and quantifiable biomarkers tools to advance clinical readouts
- NIH, Aging.Biotech.com, Ascendant Ventures to outline what they need to see to invest in longevity biotechs, helping you to shape your clinical strategy and pitch book
Join us to explore biomarkers, navigate regulatory pathways, and foster collaborations for pipeline support and commercialization.
Gain unparalleled competitive intelligence, scientific advancements and form meaningful partnerships with those solving humankind’s fundamental problem.
60+
Attendees
1
Exclusive Workshop Day
20+
Expert Speakers
3
Content Filled Days
World-Class Speaker Faculty Includes:
Attending Organizations Snapshot:
Investors
Biotechs
Large Pharma
Hear From Your Peers Why This Meeting is the Place to Be:
“The breadth and depth of the presentations was outstanding. There was little repetition whilst remaining entirely on point with respect to the mechanisms underlying aging and longevity. Absolutely outstanding speakers.”
Marilda Chung, Cureline, Inc.
“The quality of presentations and discussions led to a standout, enjoyable experience.”
Rosaly Correa-de-Auraujo, National Institute of Aging
Previously Attending Companies Include:
Download the 2024 Event Guide for More Information On:
- Full list of large pharma, fast growing longevity biotechs and investors in attendence
- Invaluable advice on how to achieve investment and partnership from investors actively looking for partnership opportunities
- Full 3-day agenda and scientific content breakdown
- and more!
Other Events in the Series:
